** Shares of therapy developer Trevi Therapeutics TRVI.O rise 21.9% to $5.24 premarket
** Co says its therapy, Haduvio, met the main goal in a mid-stage trial testing in patients with a type of chronic cough
** Says therapy showed statistically significant reduction in 24-hour cough frequency
** Currently, there are no approved treatments in the U.S. for coughing bouts that don't have no identifiable cause or those that persist despite treatment of underlying conditions
** GSK GSK.L has a chronic cough treatment in development, and Merck has an experimental drug for the disease which faced two FDA rejections in the past
** Up to last close, TRVI up 45.8% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。